A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors
| Status: | Terminated |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 8/3/2016 |
| Start Date: | February 2009 |
| End Date: | December 2012 |
Phase Ib Study To Evaluate The Safety Of Combining IGF-1R Antagonist R1507 With Multiple Standard Chemotherapy Drug Treatments In Patients With Advanced Malignancies
This study will evaluate the safety and tolerability of R1507 in combination with 12
distinct standard chemotherapy drug regimens and an additional R1507 monotherapy arm in
patients with advanced malignant neoplasms.The 12 regimens will be tested in parallel. There
are 3 subsets of patients who are eligible for the study: untreated, treated and requiring
further treatment, or treated and failed and for whom adding R1507 represents a suitable
treatment for their disease. All regimens will first test doses of R1507 which are less than
the maximally administered dose, and if tolerated, the dose will be escalated in subsequent
patients. The anticipated time on study treatment is until disease progression, and the
target sample size is 100-500 individuals.
distinct standard chemotherapy drug regimens and an additional R1507 monotherapy arm in
patients with advanced malignant neoplasms.The 12 regimens will be tested in parallel. There
are 3 subsets of patients who are eligible for the study: untreated, treated and requiring
further treatment, or treated and failed and for whom adding R1507 represents a suitable
treatment for their disease. All regimens will first test doses of R1507 which are less than
the maximally administered dose, and if tolerated, the dose will be escalated in subsequent
patients. The anticipated time on study treatment is until disease progression, and the
target sample size is 100-500 individuals.
Inclusion Criteria:
- adult patients, >=18 years of age;
- malignant neoplasms;
- failed prior standard curative therapy;
- ECOG performance Status of 0 or 1;
- adequate bone marrow, hepatic and renal function;
- life expectancy greater than 8 weeks.
Exclusion Criteria:
- chemotherapy within 2 weeks of start of therapy;
- prior irradiation within 4 weeks prior to start of therapy;
- prior treatment with agents targeting IGF-IR inhibition, or other investigational
agents;
- major surgery or significant traumatic injury within 2 weeks prior to study start;
- patients receiving concurrent antibody or immunotherapy;
- other exclusion criteria are related to specific treatment regimens.
We found this trial at
8
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials